Missense NR2F1 variant in monozygotic twins affected with the Bosch–Boonstra–Schaaf optic atrophy syndrome [PDF]
Background The Bosch‐Boonstra‐Schaaf optic atrophy syndrome (BBSOAS) is an autosomal‐dominant disorder (OMIM615722) mostly characterized by optic atrophy and/or hypoplasia, mild intellectual disability, hypotonia, seizures/infantile epilepsy.
Catia Mio +5 more
doaj +5 more sources
The phenotype‐driven computational analysis yields clinical diagnosis for patients with atypical manifestations of known intellectual disability syndromes [PDF]
Background Due to extensive clinical and genetic heterogeneity of intellectual disability (ID) syndromes, the process of diagnosis is very challenging even for expert clinicians.
Aleksandra Jezela‐Stanek +7 more
doaj +5 more sources
Second Prenatal Diagnosis of Bosch–Boonstra–Schaaf Optic Atrophy Syndrome in a Fetus With a 5q14.3q15 Deletion: A Case Report and Review of the Literature [PDF]
This case demonstrates the value of cell‐free DNA (cfDNA) screening for detecting subchromosomal microdeletions in fetuses with non‐specific prenatal screening abnormalities and no overt structural malformations on ultrasound; CMA and karyotyping ...
Ying Hao +7 more
doaj +3 more sources
A pathogenic NR2F1 gene variant disrupts transcriptional activity and causes severe neurodevelopmental delay in Bosch-Boonstra-Schaaf syndrome [PDF]
Introduction Nuclear receptor subfamily 2, group F, member 1 (NR2F1) gene variations are associated with Bosch–Boonstra–Schaaf optic atrophy syndrome.
Juan Liu +4 more
doaj +3 more sources
Novel NR2F1 variant identified by whole-exome sequencing in a patient with Bosch–Boonstra–Schaaf optic atrophy syndrome [PDF]
Bosch–Boonstra–Schaaf optic atrophy syndrome (BBSOAS) is an extremely rare autosomal dominant disorder characterized by intellectual disability, developmental delay, seizures, hypotonia, hearing loss, and optic nerve atrophy.
Ayca Kocaaga +2 more
doaj +2 more sources
Language and Cognitive Features in a Girl with Bosch–Boonstra–Schaaf Optic Atrophy Syndrome [PDF]
Bosch–Boonstra–Schaaf optic atrophy syndrome (BBSOAS) is an extremely rare neurological condition caused by a disruption in the NR2F-1 gene. The most common clinical features are optic atrophy and intellectual and developmental delay.
Ivana Bogavac +6 more
doaj +2 more sources
The Natural Course of Bosch-Boonstra-Schaaf Optic Atrophy Syndrome. [PDF]
Here, we present data on genetic variants and phenotype development of 47 individuals with Bosch‐Boonstra‐Schaaf optic atrophy syndrome, a rare neurodevelopmental disorder, highlighting the fact that the disease does not appear to be fundamentally progressive.
Valentin I +4 more
europepmc +2 more sources
Case Report: A de novo NR2F1 mutation and clinical characteristics of Bosch–Boonstra–Schaaf optic atrophy syndrome in a Chinese patient [PDF]
PurposeThis study aimed to report the clinical characteristics, genetic findings, and treatment outcomes of a Chinese patient with Bosch–Boonstra–Schaaf optic atrophy syndrome (BBSOAS) caused by a mutation in the NR2F1 gene.MethodA retrospective chart ...
Shuyu Tang +5 more
doaj +2 more sources
The NR2F1-Related 5q14.3–q21.1 deletion causing periventricular heterotopia with cerebral visual impairment: a longitudinal case report and genotype–phenotype analysis [PDF]
Large interstitial deletions spanning chromosome 5q14.3 to q21.1 and encompassing NR2F1 are rare. Existing descriptions have largely focused on structural features and presenting manifestations, with fewer reports examining functional neurodevelopmental ...
Helen St Clair Tracy +4 more
doaj +2 more sources
The spectrum of communication abilities in children with 12 rare neurodevelopmental disorders: a qualitative study with caregivers. [PDF]
Background Our aim was to update an existing model of communication ability for children with rare neurodevelopmental disorders (NDDs) by centring caregiver and family perspectives. This project is part of a larger initiative to improve the measurement of communication ability for these children in the context of clinical trials.
Zigler CK +31 more
europepmc +2 more sources

